150 related articles for article (PubMed ID: 27858845)
1. Application of whole-body FDG-PET for cancer screening in a cohort of hospital employees.
Hu C; Liu CP; Cheng JS; Chiu YL; Chan HP; Peng NJ
Medicine (Baltimore); 2016 Nov; 95(44):e5131. PubMed ID: 27858845
[TBL] [Abstract][Full Text] [Related]
2. Comparison of FDG-PET/CT for Cancer Detection in Populations With Different Risks of Underlying Malignancy.
Chan HP; Liu WS; Liou WS; Hu C; Chiu YL; Peng NJ
In Vivo; 2020; 34(1):469-478. PubMed ID: 31882515
[No Abstract] [Full Text] [Related]
3. Whole-Body
Lebech AM; Gaardsting A; Loft A; Graff J; Markova E; Bertelsen AK; Madsen JL; Andersen KF; Benzon EV; Helms M; Mathiesen LR; David KP; Kronborg G; Kjaer A
J Nucl Med; 2017 Jul; 58(7):1058-1064. PubMed ID: 28082437
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: a preliminary report.
Terauchi T; Murano T; Daisaki H; Kanou D; Shoda H; Kakinuma R; Hamashima C; Moriyama N; Kakizoe T
Ann Nucl Med; 2008 Jun; 22(5):379-85. PubMed ID: 18600415
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial.
Robin P; Le Roux PY; Planquette B; Accassat S; Roy PM; Couturaud F; Ghazzar N; Prevot-Bitot N; Couturier O; Delluc A; Sanchez O; Tardy B; Le Gal G; Salaun PY;
Lancet Oncol; 2016 Feb; 17(2):193-199. PubMed ID: 26672686
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET/CT detection of very early breast cancer in women with breast microcalcification lesions found in mammography screening.
Peng NJ; Chou CP; Pan HB; Chang TH; Hu C; Chiu YL; Fu TY; Chang HT
J Med Imaging Radiat Oncol; 2015 Aug; 59(4):445-452. PubMed ID: 25872026
[TBL] [Abstract][Full Text] [Related]
9. Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT.
Garcia-Velloso MJ; Bastarrika G; de-Torres JP; Lozano MD; Sanchez-Salcedo P; Sancho L; Nuñez-Cordoba JM; Campo A; Alcaide AB; Torre W; Richter JA; Zulueta JJ
Lung Cancer; 2016 Jul; 97():81-6. PubMed ID: 27237032
[TBL] [Abstract][Full Text] [Related]
10. Appropriate timing of surveillance intervals with whole-body
Ozturk K; Gencturk M; Caicedo-Granados E; Li F; Cayci Z
Eur J Radiol; 2019 Sep; 118():75-80. PubMed ID: 31439262
[TBL] [Abstract][Full Text] [Related]
11. Role of delayed-time-point imaging during abdominal and pelvic cancer screening using FDG-PET/CT in the general population.
Naganawa S; Yoshikawa T; Yasaka K; Maeda E; Hayashi N; Abe O
Medicine (Baltimore); 2017 Nov; 96(46):e8832. PubMed ID: 29145346
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of FDG PET/CT for surveillance in asymptomatic gastric cancer patients after curative surgical resection.
Lee JW; Lee SM; Son MW; Lee MS
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):881-888. PubMed ID: 26611426
[TBL] [Abstract][Full Text] [Related]
13. Performance of whole-body
Ozturk K; Gencturk M; Caicedo-Granados E; Li F; Cayci Z
Eur Arch Otorhinolaryngol; 2019 Mar; 276(3):847-855. PubMed ID: 30604061
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.
Lee YJ; Kim YM; Jung PS; Lee JJ; Kim JK; Kim YT; Nam JH
J Gynecol Oncol; 2018 May; 29(3):e36. PubMed ID: 29400023
[TBL] [Abstract][Full Text] [Related]
16. Role of
Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
[TBL] [Abstract][Full Text] [Related]
17. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
18. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
19. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
20.
Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
